Carvedilol therapy effects on structural and electric remodeling in chronic heart failure
Abstract
Aim. To assess the effects of combination therapy with ACE inhibitors and carvedilol on cardiac remodeling, cardiac arrhythmias, and quality of life (QoL) in patients with mild to moderate chronic heart failure (CHF).
Material and methods. The study included 109 patients with mild to moderate CHF, developed in arterial hypertension, coronary heart disease, or their combination with diabetes mellitus and obesity. Initial carvedilol dose was 6,25-25 mg/d. At baseline, 3, 6, and 9 months later, physical examination, biochemical assay, lectrocardiography,
QoL and clinical outcome assessment were performed. Doppler echocardiography and 24-hour electrocardiogram (ECG) monitoring were performed at baseline and 6 months later.
Results. CHF therapy, including the combination of ACE inhibitor and carvedilol, was associated with reduction in structural left ventricular (LV) remodeling, as well as with systolic and diastolic LV function normalization. According to 24-hour ECG monitoring data, the total number of supraventricular (including paired and grouped) and ventricular (including paired ectopic complexes) extrasystoles significantly decreased. Combination, carvedilol-including CHF therapy resulted in significant QoL and clinical prognosis improvement.
Conclusion. In patients with mild to moderate CHF, carvedilol demonstrated its clinical effectiveness, including reduced structural and electric remodeling progression.
About the Authors
E. V. Minakov
N.N. Burdenko Voronezh State Medical Academy
Russian Federation
Russian Federation
R. A. Khokhlov
Inter-regional Cardiology Center, Voronezh Regional Hospital. Voronezh
Russian Federation
Russian Federation
T. N. Kusnetsova
Inter-regional Cardiology Center, Voronezh Regional Hospital. Voronezh
Russian Federation
Russian Federation
Yu. V. Popovskaya
Inter-regional Cardiology Center, Voronezh Regional Hospital. Voronezh
Russian Federation
Russian Federation
E. E. Tsareva
Inter-regional Cardiology Center, Voronezh Regional Hospital. Voronezh
Russian Federation
Russian Federation
References
1. Фомин И.В., Беленков Ю.Н., Мареев В.Ю. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации – данные ЭПОХА-ХСН. Ж серд недостат 2003; 7(3): 112-5.
2. Национальные Рекомендации ВНОК и ОССН по диагностике и лечению ХСН (второй пересмотр). Ж серд недостат 2007; 8(1): 4-41.
3. Wijffels MCEF, Kirchhof CJHJ, Dorland R, et al. AF begets AF: a study in awake chronically instrumented goats. Circulation 1995; 92: 1954-68.
4. McMurray J. Dargie H, Ford I, et al. Carvedilol reduces supraventricular and ventricular arrhythmias after myocardial infarction: evidence from the CAPRICORN study. Circulation 2001; 104; II-700.
5. Pedersen OD, Bagger H, Kober L, Torp6Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100; 376-80.
6. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-17.
7. Antonio HM, Manuel GB, Rebollo Jose MG, et al, Use of Irbesartan to Maintain Sinus Rhythm in Patients With LongLasting Persistent Atrial Fibrillation. Circulation 2002; 106; 331-6.
8. Vermes E, Tardif J-C, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) Trials. Circulation 2003; 107: 2926-31.
9. Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidens of atrial fibrillation in patients with heart failure: results from the valsartan heart failure trial (Val-HeFT). Am Heart J 2005; 149: 548-57.
10. Гендлин Г.Е., Самсонова Е.В., Бухало О.В., Сторожаков Г.И. Методики исследования качества жизни у больных хронической недостаточностью кровообращения. Ж серд недостат 2000; 1(2): 74-80.
11. Васюк Ю.А. Возможности и ограничения эхокардиографического исследования в оценке ремоделирования левого желудочка при ХСН. Ж серд недостат 2000; 4(2): 107-10.
12. Bergstrom A, Andersson B, Edner M, et al. Effect of carvedilol on diastolic fuction in patients with heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Failure 2004; 6; 453-61.
13. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfuntion. The carvedilol and ACE-inhibitor remodelelling mild heart failure evaluation trial (CARMEN). Cardiovasc drugs and ther 2004; 18: 57-66.
14. Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. Москва «Медиа Сфера» 2002; 312 с.
15. Маркова Л.И., Радзевич А.Э. Гемодинамические эффекты карвведилола у больных аретриальной гипертонией. РФК 2006; 3: 3-9.
16. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. JAMA 2004; 292: 2227-36.
17. Doughty RN, Whalley GA, Walsh HA, et al. for the CAPRICORN Echo Substudy Investigators. Effects of Carvedilol on Left Ventricular Remodeling After Acute Myocardial Infarction The Echo Substudy. Circulation 2004; 109: 201-6.
18. Гиляревский С.Р., Столярова Н.И., Новикова Н.Ю. и др. Эффективность и безопасность применения карведилола и бисопролола при лечении хронической сердечной недостаточности у больных сахарным диабетом 2 типа. Ж серд недостат 2000; 5(4): 137-9.
Review
For citations:
Minakov E.V., Khokhlov R.A., Kusnetsova T.N., Popovskaya Yu.V., Tsareva E.E. Carvedilol therapy effects on structural and electric remodeling in chronic heart failure. Cardiovascular Therapy and Prevention. 2008;7(1):69-76. (In Russ.)
Views:
582
Email this article 
